Search Within

Andrew Michael Intlekofer

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (15)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (37)
  2. Department of Medicine (37)
  3. Department of Pathology and Laboratory Medicine (37)
  4. GSK Faculty (37)
  5. Hematologic Malignancies Research (37)
  6. Hematologic Malignancies, Division of (37)

More Groups

People
  1. Ahmet Dogan (28)
  2. Andrew Zelenetz (21)
  3. Maria Palomba (21)
  4. Steven Horwitz (19)
  5. Alison Moskowitz (18)
  6. Anita Kumar (17)

More People

Years
  1. 2025 (3)
  2. 2024 (2)
  3. 2023 (7)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (1)

More Years

Publications
  1. Blood (14)
  2. Blood Advances (2)
  3. Blood Cancer Journal (2)
  4. Haematologica (2)
  5. Hematological Oncology (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Nature Publishing Group (6)
  3. American Society of Clinical Oncology (3)
  4. Ferrata Storti Foundation (2)
  5. Nature Research (2)
  6. Wiley Blackwell (2)

More Publishers

Results (37)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma
    Journal Article

    Ganly, I.; Liu, E. M.; Kuo, F.; Makarov, V.; Dong, Y.; Park, J.; Gong, Y.; Gorelick, A. N.; Knauf, J. A.; Benedetti, E.; more...
    Science Advances (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • OncoTree: A cancer classification system for precision oncology
    Journal Article

    Kundra, R.; Zhang, H.; Sheridan, R.; Sirintrapun, S. J.; Wang, A.; Ochoa, A.; Wilson, M.; Gross, B.; Sun, Y.; Madupuri, R.; more...
    JCO Clinical Cancer Informatics (2021)

    Fulltext@MSK | Save
  • The epigenomics of sarcoma
    Review

    Nacev, B. A.; Jones, K. B.; Intlekofer, A. M.; Yu, J. S. E.; Allis, C. D.; Tap, W. D.; Ladanyi, M.; Nielsen, T. O.
    Nature Reviews Cancer (2020)

    Fulltext@MSK | Save
  • Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
    Journal Article

    Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
    Journal Article

    Intlekofer, A. M.; Shih, A. H.; Wang, B.; Nazir, A.; Rustenburg, A. S.; Albanese, S. K.; Patel, M.; Famulare, C.; Correa, F. M.; Takemoto, N.; more...
    Nature (2018)

    Fulltext@MSK | Save